← back to search

Michael Hubank

Royal Marsden Hospital ·
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Genomics and Diagnostics, Advanced Breast Cancer Therapies, Glioma Diagnosis and Treatment, and Lung Cancer Treatments and Mutations.
h-index
57
citations
13,619
works
567
NIH funding
primary concept
Biology
email

Recent publications

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer
Annals of Oncology 2024cited by 67position: middledoi
BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial
British Journal of Cancer 2024cited by 7position: middledoi
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer
ESMO Open 2022cited by 108position: middledoi
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
Molecular Cancer 2022cited by 58position: middledoi
A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot
Journal of Medical Genetics 2022cited by 30position: middledoi
Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study
JCO Precision Oncology 2022cited by 21position: middledoi
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
Nature Biotechnology 2021cited by 258position: middledoi
Genomic profile of advanced breast cancer in circulating tumour DNA
Nature Communications 2021cited by 94position: middledoi
Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA
Nature Communications 2021cited by 15position: middledoi
Response of NOTCH1-Activated Tracheal Adenoid Cystic Carcinoma to the Gamma Secretase Inhibitor Nirogacestat
JCO Precision Oncology 2021cited by 8position: middledoi
Abstract PS5-02: Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial
Cancer Research 2021cited by 4position: middledoi
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
The Lancet Oncology 2020cited by 350position: middledoi
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Cancer Discovery 2020cited by 276position: middledoi
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Nature Communications 2020cited by 258position: middledoi
Scalable and robust SARS-CoV-2 testing in an academic center
Nature Biotechnology 2020cited by 36position: middledoi
Author Correction: Scalable and robust SARS-CoV-2 testing in an academic center
Nature Biotechnology 2020cited by 6position: middledoi
Directing Therapy with Circulating Tumor DNA Analysis in Advanced Breast Cancer: The PlasmaMATCH Trial
SSRN Electronic Journal 2020cited by 1position: middledoi
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
Cancer Discovery 2018cited by 237position: middledoi
Targeting acute myeloid leukemia by drug-induced c-MYB degradation
Leukemia 2017cited by 114position: middledoi
Deep sequencing reveals persistence of cell-associated mumps vaccine virus in chronic encephalitis
Acta Neuropathologica 2016cited by 57position: middledoi
Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces
mBio 2015cited by 453position: middledoi
Albuminuria is associated with too few glomeruli and too much testosterone
Kidney International 2013cited by 44position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Rebecca Roylance · University College London Hospitals NHS Foundation Trust4 papers (2020–2021)Nicholas C. Turner · Queensland University of Technology4 papers (2020–2021)Judith M. Bliss · Institute of Cancer Research4 papers (2020–2021)Iain R. Macpherson · University of Dundee3 papers (2021–2021)Rosalind Cutts · Institute of Cancer Research3 papers (2021–2021)Kimberly C. Banks · University of Bath3 papers (2021–2021) · 3 papers (2021–2021)Lucy Kilburn · Institute of Cancer Research3 papers (2021–2021)Sarah Kernaghan · CRUK Lung Cancer Centre of Excellence3 papers (2021–2021)Laura Moretti · International Centre for Genetic Engineering and Biotechnology3 papers (2021–2021)Andrew Wardley · University of Manchester3 papers (2021–2021)Richard D. Baird · Cancer Research UK3 papers (2021–2021)Katie Wilkinson · University College London3 papers (2021–2021)Iris Faull · Guardia Civil3 papers (2021–2021)Alistair Ring · Fred Hutch Cancer Center3 papers (2021–2021)Richard B. Lanman · C.T. de Wit Graduate School for Production Ecology and Resource Conservation3 papers (2021–2021)Isaac García-Murillas · Breast Cancer Now3 papers (2021–2021)Belinda Kingston · Breast Cancer Now3 papers (2021–2021)Hannah Bye · King's College London2 papers (2021–2021)Matthew Beaney · Breast Cancer Now2 papers (2021–2021)